Roger Linington

Professor Linington is a Tier II Canada Research Chair in Chemical Biology and High-Throughput Screening in the Department of Chemistry at Simon Fraser University, Canada. He earned his PhD from the University of British Columbia on the study of sponge-derived natural products. His postdoctoral research was a joint appointment between the University of California San Diego and the Smithsonian Tropical Research Institute, which gave him the opportunity to participate in an international neglected disease drug discovery program in Panama City, Panama. Following his postdoctoral training Professor Linington joined the faculty of the Department of Chemistry and Biochemistry at the University of California Santa Cruz. Dr. Linington remained at UCSC for eight years until his move to Simon Fraser University in July of 2015 where his group is developing new metabolomics and informatics-driven discovery platforms for natural products research.

David Vocadlo

Dr. David Vocadlo is a professor in the Departments of Chemistry and Molecular Biology and Biochemistry and a Tier I Canada Research Chair in Chemical Biology at Simon Fraser University (SFU). At SFU he leads an interdisciplinary research team with a focus on developing new chemical tools to improve our understanding of how carbohydrates influence cell function, with particular emphasis on their roles in neurodegenerative diseases. He and his team have been recognized with a number of awards including the EWR Steacie Fellowship from the Natural Sciences and Engineering Council of Canada, the Horace Isbell Award of the American Chemical Society, the Teva Canada Biological Chemistry Award, and the Carbohydrate Research Award of the International Carbohydrate Organization. Based on cornerstone technology from his laboratory he co-founded Alectos Therapeutics, which has since partnered with Merck to advance OGA modulators into the clinic to combat neurodegenerative diseases. 

Sandra Keerthisinghe
Lab Manager

Sandra Keerthisinghe completed a doctorate degree focused on cell biology and molecular genetics in the Department of Botany at the University of British Columbia (UBC) in 2016.  Her graduate work concentrated on optimizing live cell, time lapse, spinning disk imaging techniques to characterize microtubule mediated mechanisms underlying plant cell morphogenesis.  During this time, she was also a laboratory manager and trained students and staff in basic microscopy techniques.  After graduating, she taught a large first year cell biology course at UBC.  Sandra joined the HTCB in 2018, where she continues to pursue her interests in live-cell imaging and image based statistical analysis.

Lisa Lin
Administrative Coordinator

Lisa Lin is pursuing her PhD in the Department of Biological Sciences at Simon Fraser University. Her project is focused on using induced pluripotent stem cells to characterized epilespy arising from abnormal heterogenous cell populations using immunofluorescence and functional techniques. She has extensive experience in financial procedures, faculty relations, and event planning.

Executive Advisory Committee

Tim Audas
Associate Professor, Molecular Biology & Biochemistry

Dr. Tim Audas is an Associate Professor and Tier II Canada Research Chair (Cellular Stress) in the Molecular Biology and Biochemistry department at Simon Fraser University. During his PhD at the University of Guelph, he became interested in understanding how cells cope with changes to their environment. Dr. Audas continued studying these stress-signalling pathways at the University of Ottawa (Postdoctoral Fellowship) and the University of Miami (Associate Scientist), before taking a faculty position at Simon Fraser University in 2016. He now leads a team of researchers that study a novel stress-induced protein aggregation pathway. These natural aggregates closely mirror the toxic plaques and tangles that form in patients suffering from Alzheimer’s, Parkinson’s, and Huntington’s diseases. Dr. Audas hopes that gaining a better understanding of how these natural aggregates assemble/disassemble will lead to new insights and therapeutic strategies for the treatment of these debilitating neurodegenerative disorders.

Lisa Julian
Assistant Professor, Biological Sciences


Robert Young
Professor, Chemistry

Robert Young is a Professor in the Department of Chemistry and the BC Leadership Chair in Pharmaceutical Genomics and Bioinformatics. Prior to joining SFU, Dr. Young was Vice-President of medicinal chemistry at the Merck Frosst Centre for Therapeutic Research where he was instrumental in leading his team in the discovery and commercialization of first in class new medications for allergies and inflammatory diseases, such as asthma and arthritis. His current research focuses on the design and synthesis of small molecule probes to aid in understanding disease processes and to discover novel targets and therapies for treatment. His contributions have been recognized by many awards including being made a Fellow of the Royal Society of Canada and a Member of the Order of Canada. He is founded of the biotechnology company Mesentech Incorporated and is actively involved in many advisory committees of national and international scientific organizations.